Stivarga: a new oral multikinase inhibitor

Stivarga (regorafenib) is indicated in metastatic colorectal cancer previously treated with fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy, or when these therapies are not suitable.

The recommended dose of Stivarga is 160mg once daily after a light low-fat meal on days 1-21 of a 28-day treatment cycle
The recommended dose of Stivarga is 160mg once daily after a light low-fat meal on days 1-21 of a 28-day treatment cycle


Regorafenib is an oral tumour deactivation agent that inhibits multiple protein kinases, including those involved in tumour angiogenesis, oncogenesis and the tumour microenvironment.1,2


The safety and efficacy of regorafenib were evaluated in the double-blind, phase III CORRECT study involving 760 patients with metastatic colorectal cancer that had progressed after failure of standard therapy.1,2

Patients were randomised to receive best supportive care plus regorafenib 160mg (n=505) or placebo (n=255) once daily for the first 3 weeks of each monthly treatment cycle. Treatment was continued until disease progression or unacceptable toxicity occured. The primary outcome measure was overall survival.1,2

Survival increased

Regorafenib produced a significant improvement in overall survival compared with placebo, of 6.4 versus 5 months (HR 0.77, 95% CI 0.64–0.94, p=0.0052). A significant improvement in progression-free survival, a secondary endpoint, was also observed (HR 0.494, p<0.000001).1,2

Safety profile

The most common adverse effects observed in patients receiving regorafenib were hand-foot skin reaction, fatigue, diarrhoea, hypertension and rash.1,2


  1. Stivarga Summary of Product Characteristics, August 2013.
  2. Grothey A et al. Lancet 2013; 381: 303–12.

View Stivarga drug record

Further information: Bayer plc

Follow MIMS on Twitter

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.